Isobolographic analysis of interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and four conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model

European Journal of Pharmacology

Volumn 602, Issue 2-3, 2009, Pages 298-305

  Luszczki, Jarogniew J ^a,b   Antkiewicz Michaluk, Lucyna ^c   Czuczwar, Stanislaw J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

1 Methyl 1,2,3,4 tetrahydroisoquinoline; Antiepileptic drugs; Isobolographic analysis; Maximal electroshock; Pharmacodynamic pharmacokinetic interaction

Indexed keywords

1 METHYL 1,2,3,4 TETRAHYDROISOQUINOLINE; CARBAMAZEPINE; ISOQUINOLINE DERIVATIVE; PHENOBARBITAL; PHENYTOIN; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; DRUG EFFECT; DRUG POTENTIATION; ELECTRIC SHOCK; MALE; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; SEIZURE; TASK PERFORMANCE;

ANIMALS; ANTICONVULSANTS; DRUG COMBINATIONS; DRUG INTERACTIONS; ELECTROSHOCK; HAND STRENGTH; MALE; MEMORY; MICE; MOTOR ACTIVITY; MUSCLE, SKELETAL; SEIZURES; TETRAHYDROISOQUINOLINES; TIME FACTORS;

EID: 58149149622     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.11.049     Document Type: Article

References (49)

1. Antkiewicz-Michaluk L., Michaluk J., Mokrosz M., Romanska I., Lorenc-Koci E., Ohta S., and Vetulani J. Different action on dopamine catabolic pathways of two endogenous 1,2,3,4-tetrahydroisoquinolines with similar antidopaminergic properties. J. Neurochem. 78 (2001) 100-108
2. Antkiewicz-Michaluk L., Karolewicz B., Romanska I., Michaluk J., Bojarski A.J., and Vetulani J. 1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. Eur. J. Pharmacol. 466 (2003) 263-269
3. Antkiewicz-Michaluk L., Wardas J., Michaluk J., Romaska I., Bojarski A., and Vetulani J. Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int. J. Neuropsychopharmacol. 7 (2004) 155-163
4. Antkiewicz-Michaluk L., Lazarewicz J.W., Patsenka A., Kajta M., Zieminska E., Salinska E., Wasik A., Golembiowska K., and Vetulani J. The mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity. J. Neurochem. 97 (2006) 846-856
5. Berenbaum M.C. What is synergy?. Pharmacol. Rev. 41 (1989) 93-141 Erratum published in 1989. Pharmacol. Rev. 41, 422
6. Boissier J.R., Tardy J., and Diverres J.C. Une nouvelle methode simple pour explorer l'action «tranquilisante»: le test de la cheminee. Med. Expert (Basel) 3 (1960) 81-84
7. Borowicz K.K., Luszczki J.J., and Czuczwar S.J. Isobolographic and subthreshold analysis of interactions among felbamate and four conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice. Epilepsia 45 (2004) 1176-1183
8. Deckers C.L.P., Czuczwar S.J., Hekster Y.A., Keyser A., Kubova H., Meinardi H., Patsalos P.N., Renier W.O., and Van Rijn C.M. Selection of antiepileptic drug polytherapy based on mechanism of action: the evidence reviewed. Epilepsia 41 (2000) 1364-1374
9. Grabovsky Y., and Tallarida R.J. Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J. Pharmacol. Exp. Ther. 310 (2004) 981-986
10. Greco W.R., Bravo G., and Parsons J.C. The search for synergy: a critical review from response surface perspective. Pharmacol. Rev. 47 (1995) 331-385
11. Ko G.Y., Brown-Croyts L.M., and Teyler T.J. The effects of anticonvulsant drugs on NMDA-EPSP, AMPA-EPSP, and GABA-IPSP in the rat hippocampus. Brain Res. Bull. 42 (1997) 297-302
12. Kotake Y., Tasaki Y., Makino Y., Ohta S., and Hirobe M. 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF. J. Neurochem. 65 (1995) 2633-2638
13. Kotake Y., Yoshida M., Ogawa M., Tasaki Y., Hirobe M., and Ohta S. Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate. Neurosci. Lett. 217 (1996) 69-71
14. Kotake Y., Taguchi R., Okuda K., Sekiya Y., Tasaki Y., Hirobe M., and Ohta S. Neuroprotective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline on cultured rat mesencephalic neurons in the presence or absence of various neurotoxins. Brain Res. 1033 (2005) 143-150
15. Leach J.P. Antiepileptic drugs: safety in numbers?. Seizure 9 (2000) 170-178
16. Litchfield J.T., and Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96 (1949) 99-113
17. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3 (1953) 285-290
18. Löscher W., and Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 2 (1988) 145-181
19. Löscher W., and Wauquier A. Use of animal models in developing guiding principles for polypharmacy in epilepsy. Epilepsy Res. Suppl. 11 (1996) 61-65
20. Löscher W., Fassbender C.P., and Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 8 (1991) 79-94
21. Luszczki J.J. Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application. Naunyn-Schmiedeberg's Arch. Pharmacol. 375 (2007) 105-114
22. Luszczki J.J. Interactions of tiagabine with ethosuximide in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for nonparallel dose-response relationship curves. Naunyn-Schmiedeberg's Arch. Pharmacol. 378 (2008) 483-492
23. Luszczki J.J., and Czuczwar S.J. Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics-a comparative study. Epilepsy Res. 56 (2003) 27-42
24. Luszczki J.J., and Czuczwar S.J. Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. Naunyn-Schmiedeberg's Arch. Pharmacol. 369 (2004) 434-446
25. Luszczki J.J., and Czuczwar S.J. Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis. Naunyn-Schmiedeberg's Arch. Pharmacol. 374 (2006) 51-64
26. Luszczki J.J., and Czuczwar S.J. Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog. Neuropsychopharmacol. Biol. Psychiatry 31 (2007) 529-538
27. Luszczki J.J., Borowicz K.K., Swiader M., and Czuczwar S.J. Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 44 (2003) 489-499
28. Luszczki J.J., Swiader M., Parada-Turska J., and Czuczwar S.J. Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice. Neuropsychopharmacology 28 (2003) 1817-1830
29. Luszczki J.J., Wojcik-Cwikla J., Andres M.M., and Czuczwar S.J. Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology 30 (2005) 958-973
30. Luszczki J.J., Antkiewicz-Michaluk L., and Czuczwar S.J. 1-Methyl-1,2,3,4-tetrahydroisoquinoline enhances the anticonvulsant action of carbamazepine and valproate in the mouse maximal electroshock seizure model. Neuropharmacology 50 (2006) 133-142
31. Luszczki J.J., Ratnaraj N., Patsalos P.N., and Czuczwar S.J. Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn-Schmiedeberg's Arch. Pharmacol. 373 (2006) 169-181
32. Luszczki J.J., Danysz W., and Czuczwar S.J. Interactions of MRZ 2/576 with felbamate, lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model. Pharmacology 81 (2008) 259-265
33. Luszczki J.J., Wu J.Z., Raszewski G., and Czuczwar S.J. Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. Naunyn-Schmiedeberg's Arch. Pharmacol. (2008) 10.1007/s00210-008-0349-9
34. Meyer O.A., Tilson H.A., Byrd W.C., and Riley M.T. A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav. Toxicol. 1 (1979) 233-236
35. Parrado J., Absi E., Ayala A., Castano A., Cano J., and Machado A. The endogenous amine 1-methyl-1,2,3,4-tetrahydroisoquinoline prevents the inhibition of complex I of the respiratory chain produced by MPP(+). J. Neurochem. 75 (2000) 65-71
36. Rogawski M.A., and Porter R.J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol. Rev. 42 (1990) 223-286
37. Rogawski M.A., Thurkauf A., Yamaguchi S., Rice K.C., Jacobson A.E., and Mattson M.V. Anticonvulsant activities of 1-phenylcyclohexylamine and its conformationally restricted analog 1,1-pentamethylenetetrahydroisoquinoline. J. Pharmacol. Exp. Ther. 249 (1989) 708-712
38. Tallarida R.J. Drug synergism and dose-effect data analysis (2000), Chapman & Hall/CRC, Boca Raton, USA
39. Tallarida R.J. An overview of drug combination analysis with isobolograms. J. Pharmacol. Exp. Ther. 319 (2006) 1-7
40. Tallarida R.J. Interactions between drugs and occupied receptors. Pharmacol. Ther. 113 (2007) 197-209
41. Tallarida R.J., Stone Jr. D.J., and Raffa R.B. Efficient designs for studying synergistic drug combinations. Life Sci. 61 (1997) PL417-PL425
42. Tasaki Y., Makino Y., Ohta S., and Hirobe M. 1-Methyl-1,2,3,4-tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities. J. Neurochem. 57 (1991) 1940-1943
43. Thull U., Kneubuhler S., Gaillard P., Carrupt P.A., Testa B., Altomare C., Carotti A., Jenner P., and McNaught K.S. Inhibition of monoamine oxidase by isoquinoline derivatives. Qualitative and 3D-quantitative structure-activity relationships. Biochem. Pharmacol. 50 (1995) 869-877
44. Twyman R.E., Rogers C.J., and Macdonald R.L. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann. Neurol. 25 (1989) 213-220
45. Venault P., Chapouthier G., de Carvalho L.P., Simiand J., Morre M., Dodd R.H., and Rossier J. Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature 321 (1986) 864-866
46. Vetulani J., Antkiewicz-Michaluk L., Nalepa I., and Sansone M. A possible physiological role for cerebral tetrahydroisoquinolines. Neurotox. Res. 5 (2003) 147-155
47. Wasik A., Romanska I., and Antkiewicz-Michaluk L. The effect of an endogenous compound 1-methyl-1,2,3,4,-tetrahydroisoquinoline on morphine-induced analgesia, dependence and neurochemical changes in dopamine metabolism in rat brain structures. J. Physiol. Pharmacol. 58 (2007) 235-252
48. Yamakawa T., and Ohta S. Biosynthesis of a parkinsonism-preventing substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline, is inhibited by parkinsonism-inducing compounds in rat brain mitochondrial fraction. Neurosci. Lett. 259 (1999) 157-160
49. Yamakawa T., Kotake Y., Fujitani M., Shintani H., Makino Y., and Ohta S. Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain. Neurosci. Lett. 276 (1999) 68-70